当前位置:首页 >财报库 > 报告详情

麦克森Mckesson(MCK)2026财年第三季度业绩电话会纪要「NYSE」(英文版)(20页).pdf

上传人: 1****1 编号:1180579 2026-04-03 20页 305.01KB

下载:

1、 Corrected Transcript 1-877-FACTSET Total Pages:20 Copyright 2001-2026 FactSet CallStreet,LLC 04-Feb-2026 McKesson Corp.(MCK)Q3 2026 Earnings Call McKesson Corp.(MCK)Q3 2026 Earnings Call Corrected Transcript 04-Feb-2026 1-877-FACTSET 2 Copyright 2001-2026 FactSet CallStreet,LLC CORPORATE PARTICIPAN

2、TS Jeni Dominguez Vice President-Investor Relations,McKesson Corp.Brian Scott Tyler Chief Executive Officer&Director,McKesson Corp.Britt J.Vitalone Executive Vice President&Chief Financial Officer,McKesson Corp.OTHER PARTICIPANTS Allen Lutz Analyst,BofA Securities,Inc.Brian Tanquilut Analyst,Jefferi

3、es LLC Lisa C.Gill Analyst,JPMorgan Securities LLC Michael Cherny Analyst,Leerink Partners LLC Eric Percher Analyst,Nephron Research LLC Glen Santangelo Analyst,Barclays Capital,Inc.Elizabeth Anderson Analyst,Evercore ISI Charles Rhyee Analyst,TD Cowen Erin Wilson Wright Analyst,Morgan Stanley&Co.LL

4、C Daniel Grosslight Analyst,Citigroup Global Markets,Inc.Kevin Caliendo Analyst,UBS Securities LLC George Hill Analyst,Deutsche Bank Securities,Inc.McKesson Corp.(MCK)Q3 2026 Earnings Call Corrected Transcript 04-Feb-2026 1-877-FACTSET 3 Copyright 2001-2026 FactSet CallStreet,LLC MANAGEMENT DISCUSSI

5、ON SECTION Operator:Welcome to McKessons Third Quarter Fiscal 2026 Earnings Conference Call.Please be advised that todays conference is being recorded.At this time,I would like to turn the call over to Jeni Dominguez,VP of Investor Relations.Please go ahead.Jeni Dominguez Vice President-Investor Rel

6、ations,McKesson Corp.Thank you,operator.Good afternoon and welcome everyone to McKessons third quarter fiscal 2026 earnings call.Today,Im joined by Brian Tyler,our Chief Executive Officer;and Britt Vitalone,our Chief Financial Officer.Brian will lead off,followed by Britt.And then well move to a que

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **业绩表现**:Q3营收1062亿美元(+11%),调整后EPS 9.34美元(+16%);全年EPS指引上调至38.80-39.20美元(+17%至19%)。 2. **业务增长**: - 肿瘤与专科业务营收130亿美元(+37%),运营利润3.66亿美元(+57%); - 生物制药服务营收15亿美元(+9%),运营利润2.77亿美元(+18%); - 北美药品分销营收883亿美元(+9%),GLP-1药物分销140亿美元(+26%)。 3. **战略进展**: - 完成挪威业务剥离,加速医疗外科业务分拆(目标2027H2 IPO); - 技术投资提升效率(如AI工具减少75%客户咨询升级)。 4. **现金流**:Q3自由现金流11亿美元,全年指引44-48亿美元;计划回购25亿美元股票。
**肿瘤业务增长?** **AI如何提效?** **政策影响几何?**
客服
商务合作
小程序
服务号
折叠